D. E. Shaw & Co., Inc. Immuneering Corp Transaction History
D. E. Shaw & Co., Inc.
- $125 Billion
- Q2 2025
Shares
2 transactions
Others Institutions Holding IMRX
# of Institutions
45Shares Held
4.12MCall Options Held
0Put Options Held
0-
Vanguard Group Inc Valley Forge, PA1.06MShares$7.13 Million0.0% of portfolio
-
Marshall Wace, LLP London, X0574KShares$3.87 Million0.0% of portfolio
-
Black Rock Inc. New York, NY533KShares$3.6 Million0.0% of portfolio
-
Iridian Asset Management LLC275KShares$1.86 Million0.75% of portfolio
-
Southport Management, L.L.C. Wilson, WY245KShares$1.65 Million4.03% of portfolio
About Immuneering Corp
- Ticker IMRX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 26,392,300
- Market Cap $178M
- Description
- Immuneering Corporation, a biopharmaceutical company, focuses on the oncology and neuroscience product candidates. Its lead product candidates include IMM-1-104, a dual-MEK inhibitor to treat patients with cancer, including pancreatic, melanoma, colorectal, and non-small cell lung cancer caused by mutations of RAS and/or RAF; and IMM-6-415 to tr...